Biopharmaceutical companies must address the frictions and challenges that have quietly infiltrated the drug development ecosystem and root them out, planting instead a new spirit of partnership and collaboration.
- Companies To Watch: Aurion Biotech
- Google Life Sciences Leader Talks AI Opportunities And 'Watch Outs' For Biopharma
- 'Doers, not Leaders': How Women Can Overcome A Common Workplace Struggle
- This Takeda Official Thinks Pharma 4.0 Won't Be Optional Much Longer
- Mid-Year M&A Outlook: Challenges And Opportunities Update
- Where Are They Now? Caribou Biosciences
- GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 2025
- An Updated View Of The Federal Segment: Veterans Affairs Formulary Management
COMPANIES TO WATCH
-
![Greg_Kunst]( "Companies To Watch: Aurion Biotech")
Companies To Watch: Aurion BiotechAurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.
-
![Mark Litton]( "Companies To Watch: Athira Pharma")
Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.
-
![Charles Hugh-Jones]( "Companies To Watch: Volastra Therapeutics")
Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow.
-
![Nicolas Poirier_OSE Immunotherapeutics]( "Companies To Watch: OSE Immunotherapeutics")
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
WHERE ARE THEY NOW
-
![Rachel Haurwitz]( "Where Are They Now? Caribou Biosciences")
Where Are They Now? Caribou BiosciencesCaribou Biosciences is gunning for a Phase 3 pivotal trial start in 2025 for lead candidate CB-010, after cutting its CAR-NK preclinical activities to focus exclusively on developing CB-010 and two additional allogeneic CAR-T therapies.
-
![Otsuka cover_Oct 2016]( "Where Are They Now? Otsuka")
Where Are They Now? OtsukaOtsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago.
-
![Armon_Sharei_450x300]( "Where Are They Now? SQZ Biotech")
Where Are They Now? SQZ BiotechSQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.
NEWSLETTER ARCHIVE
- 09.09.24 -- The Role Of Physician Intelligence In Drug Discovery And Development
- 09.09.24 -- Accelerate Development Timelines With A Robust CLD Strategy
- 09.06.24 -- How DEI Sets A High Bar For Leadership
- 09.06.24 -- Listen Now: The Allogeneic Future, mRNA Upstarts, Drug Development for DMD, and more.
- 09.05.24 -- Accelerate Development Timelines With A Robust CLD Strategy
SPOTLIGHT
Industry veteran James Sapirstein, CEO of Entero Therapeutics, discusses the company's lead candidate, a treatment for celiac disease, and makes the case for investors and Big Pharma to step up and help bring it across the finish line.
